Table 2.
The percentage of samples from 84 participants (95% CI; N) containing at least one faecal E coli isolate resistant to the tested antimicrobials; overall and stratified by hospital
| Resistance | All participants | FAH | EH | SAH |
| AMP | 53.6 (42.9 to 64.2; 45) | 56.3 (39.1 to 73.4; 18) | 55.0 (33.2 to 76.8; 11) | 50.0 (32.7 to 67.3; 16) |
| AMC | 10.7 (4.10 to 17.3; 9) | 15.6 (3.04 to 28.2; 5) | 5.0 (0 to 14.6; 1) | 9.38 (0 to 19.5; 3) |
| NAL | 25.0 (15.7 to 34.3; 21) | 28.1 (12.5 to 43.7; 9) | 25.0 (6.02 to 44.0; 5) | 21.9 (7.55 to 36.2; 7) |
| CIP | 11.9 (4.98 to 18.8; 10) | 15.6 (3.04 to 28.2; 5) | 10.0 (0 to 23.1; 2) | 9.38 (0 to 19.5; 3) |
| CHL | 16.7 (8.70 to 24.6; 14) | 15.6 (3.04 to 28.2; 5) | 20.0 (2.47 to 37.5; 4) | 15.6 (3.04 to 28.2; 5) |
| TMP | 34.5 (24.4 to 44.7; 29) | 50.0 (32.7 to 67.3; 16) | 40.0 (18.5 to 61.5; 8) | 15.6 (3.04 to 28.2; 5) |
| TET | 39.3 (28.8 to 49.7; 33) | 46.9 (29.6 to 64.2; 15) | 40.0 (18.5 to 61.5; 8) | 31.3 (15.2 to 47.3; 10) |
| BLM | 53.6 (42.9 to 64.2; 45) | 56.3 (39.1 to 73.4, 18) | 55.0 (33.2 to 76.8; 11) | 50 (32.7 to 67.3; 16) |
| QNL | 25.0 (15.7 to 34.3; 21) | 28.1 (12.5 to 43.7; 9) | 25.0 (6.02 to 44.0; 5) | 21.9 (7.55 to 36.2; 7) |
| 3GCR | 10.7 (4.10 to 17.3; 9) | 9.38 (0 to 19.5; 3) | 5.0 (0 to 14.6; 1) | 15.6 (3.04 to 28.2; 5) |
| AMR | 60.7 (50.3 to 71.2, 51) | 59.4 (42.4 to 76.4; 19) | 65.0 (44.1 to 85.9; 13) | 59.4 (42.4 to 76.4; 19) |
| MDR | 32.1 (22.2 to 42.1; 27) | 40.6 (23.6 to 57.6, 13) | 35.0 (14.1 to 55.9; 7) | 21.9 (7.55 to 36.2; 7) |
| ALL | 7.14 (1.64 to 12.7; 6) | 12.5 (1.04 to 24.0; 4) | 5.0 (0 to 14.6; 1) | 3.13 (0 to 9.15; 1) |
| ESBL | 5.95 (0.892 to 11.0; 5) | 3.13 (0 to 9.15; 1) | 5.0 (0 to 14.6; 1) | 9.38 (0 to 19.5; 3) |
ALL, resistance to all five tested antimicrobial classes (β-lactams, quinolones, chloramphenicol, trimethoprim and tetracycline); AMC, amoxicillin clavulanate resistance; AMP, ampicillin resistance; AMR, resistance to≥1 tested antimicrobial; BLM, β-lactam resistance; CHL, chloramphenicol resistance; CIP, ciprofloxacin resistance; EH, equine hospital; ESBL, sample contained ESBL-producing E coli.; FAH, farm animal hospital; MDR, resistance to≥3 tested antimicrobials; NAL, nalidixic acid resistance; QNL, quinolone resistance; SAH, small animal hospital; TET, tetracycline resistance; TMP, trimethoprim resistance; 3GCR, third-generation cephalosporin resistance